Inhibikase Therapeutics Inc (IKT)

Jun 03, 2025

Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

Jun 03, 2025

May 27, 2025

Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st

May 27, 2025

May 23, 2025

Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025

May 17, 2025

13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World

May 17, 2025

May 16, 2025

Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks

May 16, 2025

May 14, 2025

Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025

May 14, 2025

Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025

May 14, 2025

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times

May 14, 2025

May 14, 2025

Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development - Stock Titan

May 14, 2025

May 12, 2025

Barclays PLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

May 12, 2025

May 12, 2025

Former Inhibikase leader launches new biotech for midstage Parkinson's asset - Fierce Biotech

May 12, 2025

May 05, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) - PR Newswire

May 05, 2025

May 02, 2025

Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH - Seeking Alpha

May 02, 2025

May 01, 2025

Geode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

May 01, 2025

Apr 24, 2025

IKTInhibikase Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025

Apr 15, 2025

In wake of Anthos buyout, CFO McIntyre joins Inhibikase - biocentury.com

Apr 15, 2025

Apr 14, 2025

Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks

Apr 14, 2025

Apr 14, 2025

Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 14, 2025

Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN

Apr 14, 2025

Apr 14, 2025

Inhibikase Therapeutics appoints new CFO - Investing.com Australia

Apr 14, 2025

Apr 14, 2025

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewswire

Apr 14, 2025

Apr 14, 2025

Strategic Hire: Venture Capital Veteran and Life Sciences CFO Expert Takes Helm at Inhibikase - Stock Titan

Apr 14, 2025

Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025

Apr 04, 2025

In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st

Apr 04, 2025

Apr 04, 2025

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo

Apr 04, 2025

Mar 31, 2025

H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada

Mar 31, 2025

Mar 31, 2025

H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India

Mar 31, 2025

Mar 30, 2025

HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World

Mar 30, 2025

Mar 29, 2025

Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 29, 2025

Mar 28, 2025

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - The Manila Times

Mar 28, 2025

Mar 27, 2025

Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz

Mar 27, 2025

Mar 27, 2025

Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan

Mar 27, 2025

Mar 23, 2025

INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025

Mar 21, 2025

Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 05, 2025

Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research

Mar 05, 2025

Feb 25, 2025

After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury

Feb 25, 2025

Feb 24, 2025

Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria

Feb 24, 2025

Feb 24, 2025

Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire

Feb 24, 2025

Feb 24, 2025

Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com

Feb 24, 2025

Feb 24, 2025

Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks

Feb 24, 2025

Feb 24, 2025

Inhibikase enhances leadership with new appointments - Investing.com

Feb 24, 2025

Feb 24, 2025

Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World

Feb 24, 2025

Feb 18, 2025

Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks

Feb 18, 2025

Feb 18, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire

Feb 18, 2025

Feb 18, 2025

Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan

Feb 18, 2025

Feb 17, 2025

What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World

Feb 17, 2025